2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

nonsmall cell lung cancer (NSCLC)

" in MedChemExpress (MCE) Product Catalog:

76

Inhibitors & Agonists

1

Screening Libraries

1

Peptides

7

Inhibitory Antibodies

10

Natural
Products

1

Isotope-Labeled Compounds

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-153863
    MS934

    		MEK Cancer
    MS934 is a novel improved VHL-recruiting MEK 1/2 degrader. MS934 has anti-proliferation potency at inhibiting the growth of HT-29 cells with a GI50 value of 0.023 μM. MS934 can be used for the research of variety of human cancers, such as melanoma, nonsmall cell lung cancer (NSCLC), colorectal cancer, primary brain tumors, and hepatocellular carcinoma .
    MS934
  • HY-19637
    SW044248

    		Topoisomerase Cancer
    SW044248 is a non-canonical topoisomerase I inhibitor, and selectively toxic for certain non-small cell lung cancer (NSCLC) cell lines.
    SW044248
  • HY-P5005
    VIPhyb

    		Biochemical Assay Reagents Cancer
    VIPhyb (compound VIPhyb) is a vasoactive intestinal polypeptide (VIP) receptor antagonist that can be used in the study of cancers such as non-small cell lung cancer (NSCLC) .
    VIPhyb
  • HY-118263
    Dacomitinib hydrate
    15+ Cited Publications

    PF-00299804 hydrate; PF-299804 hydrate

    		 EGFR Cancer
    Dacomitinib (PF-00299804) hydrate is an orally active, irreversible pan-ErbB inhibitor. Dacomitinib hydrate can be used in the research of cancers such as metastatic non-small cell lung cancer (NSCLC) .
    Dacomitinib hydrate
  • HY-P99269
    Sibrotuzumab

    BIBH 1; Anti-Human FAP Recombinant Antibody

    		 FAP Cancer
    Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .
    Sibrotuzumab
  • HY-164513
    NHTD

    		Ras Phosphodiesterase (PDE) Cancer
    NHTD is a KRAS-PDEδ inhibitor. NHTD targets the prenyl-binding pocket of PDEδ, altering the cellular localization of KRAS, thereby inhibiting the proliferation of KRAS-mutant cancer cells and inducing apoptosis. NHTD can be used for research on KRAS-driven non-small cell lung cancer (NSCLC) .
    NHTD
  • HY-151571
    ZG1077

    		Ras Cancer
    ZG1077 is a covalent KRAS G12C inhibitor. ZG1077 can be used in the research of non-small cell lung cancer (NSCLC) .
    ZG1077
  • HY-N11912
    Soladulcoside A

    		Biochemical Assay Reagents Cancer
    Soladulcoside A is a steroidal glycoside and antineoplastic agent that can be obtained from the whole plant of Solanum nigrum. Soladulcoside A can inhibit A549 cells and has the potential to study cancers such as non-small cell lung cancer (NSCLC) .
    Soladulcoside A
  • HY-106618
    Mopidamol

    RA 233

    		 Phosphodiesterase (PDE) Cancer
    Mopidamol (RA 233), a derivative of Dipyridamole (HY-B0312), is a phosphodiesterase inhibitor. Mopidamol can be used for non-small cell lung cancer (N-SCLC) research .
    Mopidamol
  • HY-147802
    EGFR-IN-59

    		EGFR Apoptosis Cancer
    EGFR-IN-59 (Compound 8c) is a EGFR inhibitor (IC50=190 nM) and apoptosis inducer. EGFR-IN-59 exhibits cytotoxicity against non-small lung cancer cell lines (A549) and normal lung fibroblasts (WI38) with IC50s of 8.62 and 52.6 µM, respectively. EGFR-IN-59 can be used for the research of various cancers such as non-small cell lung cancer (NSCLC), head and neck cancer, breast cancer and colorectal cancer .
    EGFR-IN-59
  • HY-155163
    APG-2449

    		Anaplastic lymphoma kinase (ALK) ROS Kinase FAK Others
    APG-2449 is an orally active ALK/ROS1/FAK inhibitor. APG-2449 shows antitumor activity in mouse models of non-small cell lung cancer (NSCLC) .
    APG-2449
  • HY-112870A
    Firmonertinib mesylate
    2 Publications Verification

    Alflutinib mesylate; Furmonertinib mesylate; AST2818 mesylate

    		 EGFR Cancer
    Firmonertinib (Alflutinib) mesylate is is a potent inhibitor of EGFR. Firmonertinib mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib has the potential for the research of cancer diseases, especially non-small cell lung cancer (NSCLC) .
    Firmonertinib mesylate
  • HY-112870
    Firmonertinib

    Alflutinib; Furmonertinib; AST2818

    		 EGFR Cancer
    Firmonertinib (Alflutinib) is a potent inhibitor of EGFR. Firmonertinib inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib has the potential for the research of cancer diseases, especially non-small cell lung cancer (NSCLC) .
    Firmonertinib
  • HY-137433
    Befotertinib
    1 Publications Verification

    D-0316

    		 EGFR Cancer
    Befotertinib (D-0316) is the third-generation EGFR tyrosine kinase inhibitor. Befotertinib can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC) .
    Befotertinib
  • HY-P99223
    Tovetumab

    MEDI-575

    		 PDGFR Cancer
    Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC) .
    Tovetumab
  • HY-110171
    iMDK
    1 Publications Verification

    		 PI3K Cancer
    iMDK is a potent PI3K inhibitor and inhibits the growth factor MDK (also known as midkine or MK). iMDK suppresses non-small cell lung cancer (NSCLC) cooperatively with A MEK inhibitor without harming normal cells and mice .
    iMDK
  • HY-119182
    Mitonafide

    NSC 300288

    		 DNA/RNA Synthesis Cancer
    Mitonafide (NSC 300288) is a cytostatic agent. Mitonafide binds to double-stranded DNA through intercalation, and inhibits DNA and RNA synthesis. Mitonafide is an antitumor agent that can be used in the research of cancers, such as non-small cell lung cancer (NSCLC), leukemia .
    Mitonafide
  • HY-153356
    MRT-2359

    		Apoptosis Cancer
    MRT-2359 is a potent, orally active and selective GSPT1 depressant (IC50: >30 nM and <300 nM) that specifically induces apoptosis dependent on protein translation. MRT-2359 exhibits significant and preferred anti-proliferative activity in a variety of cancer cell lines, especially MYC-driven cell lines, such as non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) with high expression of N-Myc or L-Myc. MRT-2359 inhibits the growth of drug-resistant NSCLC and SCLC cells, making it suitable for cancer research .
    MRT-2359
  • HY-19642A
    Glesatinib hydrochloride
    2 Publications Verification

    MGCD265 hydrochloride

    		 TAM Receptor c-Met/HGFR Cancer
    Glesatinib hydrochloride (MGCD265 hydrochloride) is an orally active, potent MET/SMO dual inhibitor. Glesatinib hydrochloride, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC) .
    Glesatinib hydrochloride
  • HY-19642
    Glesatinib

    MGCD265

    		 TAM Receptor c-Met/HGFR Cancer
    Glesatinib (MGCD265) is an orally active, potent MET/SMO dual inhibitor. Glesatinib, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC) .
    Glesatinib
  • HY-137433A
    Befotertinib mesylate

    D-0316 mesylate

    		 EGFR Cancer
    Befotertinib (D-0316) mesylate is the third-generation EGFR tyrosine kinase inhibitor. Befotertinib (D-0316) mesylate can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC) .
    Befotertinib mesylate
  • HY-110171A
    iMDK quarterhydrate
    1 Publications Verification

    		 PI3K Cancer
    iMDK quarterhydrate is a potent PI3K inhibitor and inhibits the growth factor MDK (also known as midkine or MK). iMDK quarterhydrate suppresses non-small cell lung cancer (NSCLC) cooperatively with A MEK inhibitor without harming normal cells and mice .
    iMDK quarterhydrate
  • HY-N3764
    Diosbulbin C

    		Akt Dihydrofolate reductase (DHFR) Endogenous Metabolite Others
    Diosbulbin C is a diterpene lactone component, which can be extracted from traditional Chinese medicine Dioscorea bulbifera L.. Diosbulbin C possesses high anticancer activity in non-small cell lung cancer (NSCLC). Diosbulbin C could induce cell cycle arrest at G0/G1 phase in NSCLC. Diosbulbin C also inhibits the proliferation of NSCLC cells, possibly by downregulating the expression/activation of AKT, DHFR, and TYMS .
    Diosbulbin C
  • HY-117366
    PS432

    		PKC Cancer
    PS432 is a PKC inhibitor with IC50s of 16.9 μM (PKCι) and 18.5 μM (PKCζ), respectively. PS432 effectively inhibits the proliferation of non-small cell lung cancer cells (NSCLCs) and tumor growth in mouse xenograft models .
    PS432
  • HY-W423595
    BEBT-109

    		EGFR Cancer
    BEBT-109 is a potent pan-mutant-selective EGFR inhibitor. BEBT-109 has improved pharmacokinetic properties. BEBT-109 can be used for multiple mutant-EGFR-driven non-small cell lung cancer (NSCLC) research .
    BEBT-109
  • HY-114358
    Tamnorzatinib

    ONO-7475

    		 TAM Receptor Trk Receptor Cancer
    Tamnorzatinib (ONO-7475) is a potent, selective, and orally active Axl/Mer inhibitor with IC50 values of 0.7 nM and 1.0 nM, respectively. Tamnorzatinib sensitizes AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs, suppresses the emergence and maintenance of tolerant cells. Tamnorzatinib combines with Osimertinib (HY-15772) provides a bright promise for the study of EGFR-mutated non-small cell lung cancer (NSCLC).
    Tamnorzatinib
  • HY-P99827
    Cobolimab

    TSR-022; GSK4069889

    		 Tim3 Cancer
    Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC) .
    Cobolimab
  • HY-107553
    Chetomin

    		HSP Apoptosis Cancer
    Chetomin, an active component of Chaetomium globosum, is a heat shock protein 90/hypoxia-inducible factor 1 alpha (Hsp90/HIF1α) pathway inhibitor. Chetomin is a potent, nontoxic non-small cell lung cancer cancer stem cells (NSCLC CSC)-targeting molecule .
    Chetomin
  • HY-147281
    BAY 1135626

    		Drug-Linker Conjugates for ADC Cancer
    BAY 1135626 is used to synthesize BAY 1129980, and use to anti-tumor research. BAY 1129980 is a Auristatin-based anti-C4.4A (LYPD3) antibody–agent conjugate (ADC), is used to non–small cell lung cancer (NSCLC) research .
    BAY 1135626
  • HY-161030
    EGFR-IN-92

    		EGFR Cancer
    EGFR-IN-92 (compound 15) is an allosteric T790M/L858R double mutant EGFR inhibitor. EGFR-IN-92 shows antiproliferative activity against H1975 non-small lung cancer (NSCLC) cancer cells expressing double mutant EGFR .
    EGFR-IN-92
  • HY-N13164
    Polygalacin D3

    		PI3K Akt Apoptosis Cancer
    Polygalacin D3 is a triterpenoid saponin compound that can be extracted from the roots of the balloon flower. Polygalacin D3 can inhibit the proliferation of non-small cell lung cancer (NSCLC) cell lines by blocking the PI3K/Akt pathway, and it induces cell cycle arrest and cell apoptosis .
    Polygalacin D3
  • HY-77493
    (rel)-Tivantinib

    (rel)-ARQ 197; (rel)-(3R,4R)-ARQ 198

    		 Others Cancer
    (rel)-Tivantinib is a potent and highly selective inhibitor of the receptor tyrosine kinase c-MET. (rel)-Tivantinib has two novel targets, GSK3α and GSK3β, which play an important role in the cellular mechanism of non-small cell lung cancer (NSCLC) .
    (rel)-Tivantinib
  • HY-138751A
    limertinib diTFA

    ASK120067 diTFA

    		 EGFR Cancer
    limertinib (ASK120067) diTFA is a potent and orally active inhibitor of EGFR T790M (IC50: 0.3 nM) with selectivity over EGFR WT (IC50: 6.0 nM). limertinib diTFA is a third-generation EGFR-TKI for the research of non-small cell lung cancer (NSCLC) .
    limertinib diTFA
  • HY-163657
    HER2-IN-20

    		EGFR Cancer
    HER2-IN-20 (compound 32) is a potent and selective HER2 WT and HER2 YVMA inhibitor with IC50 values of 49, 42 nM, respectively. HER2-IN-20 has the potential for the research of non-small cell lung cancer (NSCLC) .
    HER2-IN-20
  • HY-123766
    EGFR-IN-99

    		EGFR Cancer
    EGFR-IN-99 (compound 1a) is a potent EGFR and HER2 Exon 20 insertion mutant inhibitor. EGFR-IN-99 has excellent antiproliferative activity against DFCI127 cells, with an EC50 of 11.5 nM. EGFR-IN-99 can be used for the research of non-small cell lung cancer (NSCLC) .
    EGFR-IN-99
  • HY-13299
    MK-8033
    2 Publications Verification

    		 c-Met/HGFR Cancer
    MK-8033 is an orally active ATP competitive c-Met/Ron dual inhibitor (IC50s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs) .
    MK-8033
  • HY-13299A
    MK-8033 hydrochloride
    2 Publications Verification

    		 c-Met/HGFR Cancer
    MK-8033 hydrochloride is an orally active ATP competitive c-Met/Ron dual inhibitor (IC50s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 hydrochloride can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs) .
    MK-8033 hydrochloride
  • HY-147259
    Dalmelitinib

    		c-Met/HGFR Cancer
    Dalmelitinib is an orally active selective c-Met kinase inhibitor (IC50: 2.9 nM) that binds to the ATP-binding region of c-Met. Dalmelitinib induces the phosphorylation of MET, partially or completely inhibits the phosphorylation of AKT and ERK. Dalmelitinib potently inhibits cancer cell (c-Met oncogene amplification) proliferation, and is used for the research of cancers like human non-small cell lung cancer (NSCLC) .
    Dalmelitinib
  • HY-151377
    RET-IN-19

    		RET EGFR Aurora Kinase c-Fms MAP4K Cancer
    RET-IN-19 (compound 59) is a potent RET inhibitor, with IC50 values of 6.8 and 13.51 nM against RET-wt and RET V804M, respectively. RET-IN-19 shows anticancer activity. RET-IN-19 can be used for non-small cell lung cancer (NSCLC) research .
    RET-IN-19
  • HY-158058
    WYJ-2

    		Toll-like Receptor (TLR) Pyroptosis Inflammation/Immunology Cancer
    WYJ-2 is a selective agonist for toll-like receptor 2/1 (TLR2/1) with EC50 of 18.57 nM in human TLR2 and TLR1 transient-cotransfected HEK 293T cells. WYJ-2 induces pyroptosis and exhibits anticancer activity against non-small cell lung cancer (NSCLC) .
    WYJ-2
  • HY-144680
    BLU-945

    ZL-2313

    		 EGFR Cancer
    BLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can effectively inhibit EGFR with L858R and/or exon 19 deletion mutation, T790M mutation and C797S mutation. BLU-945 can be used for the research of lung cancer including non-small cell lung cancer (NSCLC) .
    BLU-945
  • HY-143466
    ULK1-IN-2

    		FAK ULK AMPK Apoptosis Autophagy Cancer
    ULK1-IN-2 (compound 3s) is a potent ULK1 inhibitor. ULK1-IN-2 shows highest cytotoxic effect against cancer cell lines, with IC50 of 1.94 μM in A549. ULK1-IN-2 can induce apoptosis and simultaneously block autophagy, and can be used to study NSCLC (Non-small cell lung cancer) .
    ULK1-IN-2
  • HY-151606
    Akt3 degrader 1

    		Akt Cancer
    Akt3 degrader 1 (compound 12l) is a selective Akt3 degrader that overcomes Osimertinib (HY-15772)-induced resistance in H1975OR NSCLC cells. Akt3 degrader 1 also has anti-proliferative activity and significantly inhibits tumour growth in mice. Akt3 degrader 1 can be used in the study of drug-resistant non-small cell lung cancer .
    Akt3 degrader 1
  • HY-P99379
    Nidanilimab (Nadunolimab)

    CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab)

    		 Interleukin Related Cancer
    Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .
    Nidanilimab (Nadunolimab)
  • HY-13615
    Folate-FTIC

    EC-17

    		 Fluorescent Dye Others Cancer
    Folate-FTIC (EC-17) is a folic acid derivative that binds to fluorescein isothiocyanate (FITC) to give it fluorescent labeling properties. Folate-ftic is used to induce the formation of pseudo-immunological synapses between anti-FITC CAR T cells and target cells expressing Folate receptors (FRα or FRβ). Folate-FTIC can be used to develop controlled CAR-T cell therapies for research in non-small cell lung cancer (NSCLC) .
    Folate-FTIC
  • HY-164426
    HEI3090

    		P2X Receptor Interleukin Related IFNAR Inflammation/Immunology Cancer
    HEI3090 is a P2X7R activator. HEI3090 stimulates dendritic cells expressing P2X7R to produce IL-18, which subsequently promotes Natural Killer cells and CD4 T cells within tumors to produce IFN-γ, leading to a sustained antitumor response. HEI3090 can be used to enhance the efficacy of αPD-1 therapy in non-small cell lung cancer (NSCLC) .
    HEI3090
  • HY-50687
    (3S,4S)-Tivantinib

    (3S,4S)-ARQ 197; ARQ 198

    		 Others Cancer
    (3S,4S)-Tivantinib is a potent and highly selective inhibitor of the receptor tyrosine kinase c-MET. (3S,4S)-Tivantinib has two novel targets, GSK3α and GSK3β, which play an important role in the cellular mechanism of non-small cell lung cancer (NSCLC) .
    (3S,4S)-Tivantinib
  • HY-148494
    Tivumecirnon

    FLX475

    		 CCR Inflammation/Immunology Cancer
    Tivumecirnon (FLX475) is an orally bioactive, selective CCR4 antagonist. Tivumecirnon can block the recruitment of immunosuppressive regulatory T cells (Treg) into the tumor microenvironment, leading to enhanced antitumor activity. Tivumecirnon has antitumor activity on EBV+ NK/T cell lymphoma and non-small cell lung cancer (NSCLC) combined with Pembrolizumab (HY-P9902). Tivumecirnon is promising for research of broad range of tumor types .
    Tivumecirnon
  • HY-157526
    EGFR-TK-IN-1

    		EGFR Apoptosis Cancer
    EGFR-TK-IN-1 (compound 7o) is a potent mutant EGFR inhibitor with IC50 of 8.5 nM an 9.3 nM against EGFR L858R/T790M and EGFR Del19.EGFR-TK-IN-1 showes strong antiproliferative effects against EGFR mutant-driven non-small cell lung cancer (NSCLC) cells and induces cell apoptosis .
    EGFR-TK-IN-1
  • HY-121537
    CAY10404

    		COX Akt Apoptosis Neurological Disease Inflammation/Immunology Cancer
    CAY10404 is a potent and selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 1 nM and a selectivity index (SI; COX-1 IC50/COX-2 IC50) of >500000. CAY10404 is a potent PKB/Akt and MAPK signaling pathways inhibitor and induces apoptosis in non-small cell lung cancer (NSCLC) cells. CAY10404, a diarylisoxazole, has good analgesic, anti-inflammatory, and anti-cancer activities .
    CAY10404

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: